ArticleHaematologica2019

Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all?

William Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.